|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Vincenzi B, Santini D and Tonini G:
Renal-cell carcinoma. N Engl J Med. 354:1095–1096. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lam JS, Leppert JT, Belldegrun AS and
Figlin RA: Novel approaches in the therapy of metastatic renal cell
carcinoma. World J Urol. 23:202–212. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Volpe A and Patard JJ: Prognostic factors
in renal cell carcinoma. World J Urol. 28:319–327. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ljungberg B, Bensalah K, Canfield S,
Dabestani S, Hofmann F, Hora M, Kuczyk MA, Lam T, Marconi L,
Merseburger AS, et al: EAU guidelines on renal cell carcinoma: 2014
update. Eur Urol. 67:913–924. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Simon HH, Thuret S and Alberi L: Midbrain
dopaminergic neurons: Control of their cell fate by the engrailed
transcription factors. Cell Tissue Res. 318:53–61. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Morgan R, Boxall A, Bhatt A, Bailey M,
Hindley R, Langley S, Whitaker HC, Neal DE, Ismail M, Whitaker H,
et al: Engrailed-2 (En2): A highly specific urinary biomarker for
the early diagnosis of prostate cancer. Clin Cancer Res.
17:1090–1098. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Martin NL, Saba-El-Leil MK, Sadekova S,
Meloche S and Sauvageau G: EN2 is a candidate oncogene in human
breast cancer. Oncogene. 24:6890–6901. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Morgan R, Bryan RT, Javed S, Launchbury F,
Zeegers MP, Cheng KK, James ND, Wallace DM, Hurst CD, Ward DG, et
al: Expression of Engrailed-2 (EN2) protein in bladder cancer and
its potential utility as a urinary diagnostic biomarker. Eur J
Cancer. 49:2214–2222. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lai CY, Pan B, Luo Y, Liang WB, Chen J, Ye
DM, Guo JN, Li L and Su ZX: Engrailed-2 is down-regulated but also
ectopically expressed in clear cell renal cell carcinoma. Mol Biol
Rep. 41:3651–3657. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Fang JC, Zhang H and Jin SF: Epigenetics
and cervical cancer: From pathogenesis to therapy. Tumor Biol.
35:5083–5093. 2014. View Article : Google Scholar
|
|
12
|
Hauser S, Zahalka T, Fechner G, Muller SC
and Ellinger J: Serum DNA hypermethylation in patients with kidney
cancer: Results of a prospective study. Anticancer Res.
33:4651–4656. 2013.PubMed/NCBI
|
|
13
|
Chmelarova M, Krepinska E, Spacek J, Laco
J, Beranek M and Palicka V: Methylation in the p53 promoter in
epithelial ovarian cancer. Clin Transl Oncol. 15:160–163. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Cancer Genome Atlas Research Network:
Comprehensive molecular characterization of clear cell renal cell
carcinoma. Nature. 499:43–49. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Guinan P, Sobin LH, Algaba F, Badellino F,
Kameyama S, MacLennan G and Novick A: TNM staging of renal cell
carcinoma: Workgroup No. 3. Union international contre le cancer
(UICC) and the American joint committee on cancer (AJCC). Cancer.
80:992–993. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Japanease Urological Association, .
General Rule for Clinical and Pathological Studies on Renal Cell
Carcinoma. 3rd. Kanehara Company; Tokyo: 1999
|
|
17
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Grier DG, Thompson A, Kwasniewska A,
McGonigle GJ, Halliday HL and Lappin TR: The pathophysiology of HOX
genes and their role in cancer. J Pathol. 205:154–171. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lewis MT: Homeobox genes in mammary gland
development and neoplasia. Breast Cancer Res. 2:158–169. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kelly ZL, Michael A, Butler-Manuel S,
Pandha HS and Morgan RG: HOX genes in ovarian cancer. J Ovarian
Res. 4:162011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Veraksa A, Del Campo M and McGinnis W:
Developmental patterning genes and their conserved functions: From
model organisms to humans. Mol Genet Metab. 69:85–100. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hanks M, Wurst W, Anson-Cartwright L,
Auerbach AB and Joyner AL: Rescue of the En-1 mutant phenotype by
replacement of En-1 with En-2. Science. 269:679–682. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Marszałł MP, Sroka W, Adamowski M, Słupski
P, Jarzemski P, Siódmiak J and Odrowąż-Sypniewska G: Engrailed-2
protein as a potential urinary prostate cancer biomarker: A
comparison study before and after digital rectal examination. Eur J
Cancer Prev. 24:51–56. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Pandha H, Sorensen KD, Orntoft TF, Langley
S, Hoyer S, Borre M and Morgan R: Urinary engrailed-2 (EN2) levels
predict tumour volume in men undergoing radical prostatectomy for
prostate cancer. BJU Int. 110:E287–E292. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Morgan R, Boxall A, Bhatt A, Bailey M,
Hindley R, Langley S, Whitaker HC, Neal DE, Ismail M, Whitaker H,
et al: Engrailed-2 (EN2): A tumor specific urinary biomarker for
the early diagnosis of prostate cancer. Clin Cancer Res.
17:1090–1098. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lai CY, Xu Y, Yu GS, Wu X, Li YF, Pan B,
Heng BL, Xue YJ and Su ZX: Engrailed-2 might play an anti-oncogenic
role in clear-cell renal cell carcinoma. J Mol Histol. 47:229–237.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Farago M, Dominguez I, Landesman-Bollag E,
Xu X, Rosner A, Cardiff RD and Seldin DC: Kinase-inactive glycogen
synthase kinase 3beta promotes Wnt signaling and mammary
tumorigenesis. Cancer Res. 65:5792–5801. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Cao Q, Lu X and Feng YJ: Glycogen synthase
kinase-3beta positively regulates the proliferation of human
ovarian cancer cells. Cell Res. 16:671–677. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kang T, Wei Y, Honaker Y, Yamaguchi H,
Appella E, Hung MC and Piwnica-Worms H: GSK-3 beta targets Cdc25A
for ubiquitin-mediated proteolysis and GSK-3 beta inactivation
correlates with Cdc25A overproduction in human cancers. Cancer
Cell. 13:36–47. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Mai W, Kawakami K, Shakoori A, Kyo S,
Miyashita K, Yokoi K, Jin M, Shimasaki T, Motoo Y and Minamoto T:
Deregulated GSK3{beta} sustains gastrointestinal cancer cells
survival by modulating human telomerase reverse transcriptase and
telomerase. Clin Cancer Res. 15:6810–6819. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Shah N and Sukumar S: The Hox genes and
their roles in oncogenesis. Nat Rev Cancer. 10:361–371. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Miao J, Wang Z, Provencher H, Muir B,
Dahiya S, Carney E, Leong CO, Sgroi DC and Orsulic S: HOXB13
promotes ovarian cancer progression. Proc Natl Acad Sci USA.
104:17093–17098. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wang Z, Dahiya S, Provencher H, Muir B,
Carney E, Coser K, Shioda T, Ma XJ and Sgroi DC: The prognostic
biomarkers HOXB13, IL17BR, and CHDH are regulated by estrogen in
breast cancer. Clin Cancer Res. 13:6327–6334. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Jung C, Kim RS, Zhang HJ, Lee SJ and Jeng
MH: HOXB13 induces growth suppression of prostate cancer cells as a
repressor of hormone-activated androgen receptor signaling. Cancer
Res. 64:9185–9192. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Abate-Shen C: Deregulated homeobox gene
expression in cancer: Cause or consequence? Nat Rev Cancer.
2:777–785. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
36
|
Abollo-Jiménez F, Campos-Sánchez E,
Toboso-Navasa A, Vicente-Dueñas C, González-Herrero I,
Alonso-Escudero E, González M, Segura V, Blanco O, Martínez-Climent
JA, et al: Lineage-specific function of Engrailed-2 in the
progression of chronic myelogenous leukemia to T-cell blast crisis.
Cell Cycle. 13:1717–1726. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
37
|
Lambert SR, Witt H, Hovestadt V, Zucknick
M, Kool M, Pearson DM, Korshunov A, Ryzhova M, Ichimura K, Jabado
N, et al: Differential expression and methylation of brain
developmental genes define location-specific subsets of pilocytic
astrocytoma. Acta Neuropathol. 126:291–301. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Slater AA, Alokail M, Gentle D, Yao M,
Kovacs G, Maher ER and Latif F: DNA methylation profiling
distinguishes histological subtypes of renal cell carcinoma.
Epigenetics. 8:252–267. 2013. View Article : Google Scholar : PubMed/NCBI
|
